Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

216 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A preliminary report of a Phase II study of folinic acid, 5-fluorouracil, irinotecan (FOLFIRI) plus sunitinib with toxicity, efficacy, pharmacokinetics, biomarker, imaging data in patients with colorectal cancer with liver metastases as 1st line treatment.
Mross K, Büchert M, Fasol U, Jaehde U, Kanefendt F, Strumberg D, Arends J, Hense J, Moritz B, Fischer R, Scheulen ME. Mross K, et al. Among authors: jaehde u. Int J Clin Pharmacol Ther. 2011 Jan;49(1):96-8. Int J Clin Pharmacol Ther. 2011. PMID: 21176744 Clinical Trial. No abstract available.
FOLFIRI and sunitinib as first-line treatment in metastatic colorectal cancer patients with liver metastases--a CESAR phase II study including pharmacokinetic, biomarker, and imaging data.
Mross K, Scheulen M, Strumberg D, Kuhlmann J, Kanefendt F, Sörgel F, Jaehde U, Burkholder I, Moritz B, Büchert M. Mross K, et al. Among authors: jaehde u. Int J Clin Pharmacol Ther. 2014 Aug;52(8):642-52. doi: 10.5414/CP202109. Int J Clin Pharmacol Ther. 2014. PMID: 24800922 Clinical Trial.
Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib-Treated Cancer.
Diekstra MH, Fritsch A, Kanefendt F, Swen JJ, Moes D, Sörgel F, Kinzig M, Stelzer C, Schindele D, Gauler T, Hauser S, Houtsma D, Roessler M, Moritz B, Mross K, Bergmann L, Oosterwijk E, Kiemeney LA, Guchelaar HJ, Jaehde U. Diekstra MH, et al. Among authors: jaehde u. CPT Pharmacometrics Syst Pharmacol. 2017 Sep;6(9):604-613. doi: 10.1002/psp4.12210. Epub 2017 Jul 13. CPT Pharmacometrics Syst Pharmacol. 2017. PMID: 28571114 Free PMC article. Clinical Trial.
Oxaliplatin-DNA adduct formation in white blood cells of cancer patients.
Pieck AC, Drescher A, Wiesmann KG, Messerschmidt J, Weber G, Strumberg D, Hilger RA, Scheulen ME, Jaehde U. Pieck AC, et al. Among authors: jaehde u. Br J Cancer. 2008 Jun 17;98(12):1959-65. doi: 10.1038/sj.bjc.6604387. Epub 2008 May 27. Br J Cancer. 2008. PMID: 18506148 Free PMC article. Clinical Trial.
[Bortezomib].
Simons S, Scheulen ME, Jaehde U. Simons S, et al. Among authors: jaehde u. Dtsch Med Wochenschr. 2006 Feb 3;131(5):214-8. doi: 10.1055/s-2006-924951. Dtsch Med Wochenschr. 2006. PMID: 16440269 Review. German. No abstract available.
216 results